- US-listed companies
- Kiniksa Pharmaceuticals International, plc
- Income statement
Kiniksa Pharmaceuticals International, plc (KNSA) Income statement
Market cap
$9.3B
P/E ratio
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | - | - | 39 | 220 | 270 | 423 |
| Revenue growth (%) | - | - | - | - | |||
| Cost of revenue | - | - | - | 9 | - | - | 61 |
| Research & development | 87 | 135 | 112 | 99 | 65 | 76 | 112 |
| Selling, general & administrative | - | - | - | 86 | 98 | 129 | 168 |
| Operating margin (%) | - | - | - | ||||
| Operating expenses | 108 | 170 | 157 | - | - | - | - |
| Operating income | -108 | -170 | -157 | -157 | 10 | -25 | -46 |
| Income before tax | -103 | -164 | -156 | -157 | 11 | -17 | -36 |
| Pretax margin (%) | - | - | - | -406.1 | 5 | -6.2 | -8.5 |
| Provision for income taxes | -0 | -2 | 5 | 1 | -172 | -31 | 7 |
| Effective tax rate (%) | |||||||
| Net income | -103 | -162 | -161 | -158 | 183 | 14 | -43 |
| Net income margin (%) | - | - | - | ||||
| Earnings per share | - | - | - | -2.3 | 2.64 | 0.2 | -0.6 |
| Diluted EPS | - | - | - | -2.3 | 2.6 | 0.2 | -0.6 |